H. Lundbeck A/S
LUN.CO
NASDAQ Copenhagen172.70
DKK
+1.60
- -
H. Lundbeck A/S
LUN.CO
(NASDAQ Copenhagen)
Recent
price
172.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- H. Lundbeck A/S is a global pharmaceutical company specializing in the research, development, manufacture, and marketing of pharmaceuticals primarily for the treatment of brain diseases. Its core products include pharmaceutical treatments for depression, schizophrenia, Parkinson's disease, Alzheimer's disease, epilepsy, and migraine; these comprise branded medicines such as Cipralex, Lexapro, Azilect, and Abilify Maintena. Lundbeck offers a portfolio of innovative and developed drug therapies targeting neurological and psychiatric conditions, distributed across Europe, the Americas, and Asia-Pacific regions. The company operates through a combination of R&D, manufacturing, and marketing affiliates and is headquartered in Copenhagen, Denmark, having been founded in 1915. In recent years, Lundbeck has focused on expanding its portfolio through strategic acquisitions and product launches aimed at broadening its presence in the neuroscience pharmaceutical market. Major developments include key partnerships and licensing agreements to enhance its pipeline and commercial footprint, alongside new drug submissions and launches in both established and emerging markets. The company continues to invest significantly in neuroscience-focused R&D, reinforcing its global position in brain health therapeutics. There have been no recent name changes or reorganizations reported within the last two years. Lundbeck operates within the pharmaceutical industry, serving the specialty market segment of central nervous system (CNS) disorders with a strong foothold in chronic and complex brain diseases. Its customer base includes hospitals, healthcare providers, and pharmacies worldwide. The company's subsidiaries and affiliates support its international operations, and it is publicly listed on the Copenhagen Stock Exchange under the ticker LUN.CO. This comprehensive scope positions Lundbeck as a key player in global brain health pharmaceutical development and commercialization.